Condition: Medicated for patients suffering from Pulmonary/Respiratory Diseases.
Ease of Use: ★★★★
Cinqair (reslizumab) is an interleukin-5 antagonist monoclonal antibody which is generally recommended for the patients suffering from extreme asthma, It is prescribed to patients who are 18 years old and over with an eosinophilic phenotype.
It is not recommended for other problems which are caused by eosinophils or unexpected breathing problems.
FDA Approval
The FDA approval for Cinagar was based on the 4 double-blind, random, placebo controlled trials in 1,028 adult patients and adolescent patients with severe asthma. Cinqair 3 mg/kg and Placebo was given to patients for every 4 weeks as treatment for asthma. When compared with placebo, patients who received Cinqair had decline in asthma exacerbation of equal to 59%.
There was even an important improvement in lung function and asthma. As a solution, it is supplied for intravenous administration over time of 20-50 minutes. The approval was given in March 2016
Dosage:
The recommended dose of Cingair is 3 mg/kg once for every 4 weeks administered by intravenous infusion over 20-50 minutes.
Side-effects: Side-effects of Cinqair may include oropharyngeal pain but it is not necessary. Some times after taking it, the patient may suddenly suffer from allergic reactions.
Itching, nausea or abdominal discomfort, breathing problems, paleness, skin rash, swelling of face, lips, mouth, or tongue, flushing, hypotension symptoms like fainting, dizziness, confusion, light headedness, fast heart beat may be the symptoms which are associated along with allergic reactions.
